<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (CADM1/TSLC1), a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor involving in cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, is frequently inactivated in several <z:mp ids='MP_0002038'>carcinomas</z:mp> due to promoter hypermethylation </plain></SENT>
<SENT sid="1" pm="."><plain>But alterations of CADM1/TSLC1 in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and clinical significance have not been elucidated yet </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to determine the role of functional inactivation of CADM1/TSLC1 gene in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and its potential as a novel epigenetic marker for clinical assessment of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We measured CADM1/TSLC1 expression levels in 8 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, 54 primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and their corresponding non-cancerous tissues by reverse transcription polymerase chain reaction, western blot analysis and immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed CADM1/TSLC1 promoter methylation status by <z:chebi fb="0" ids="17137">bisulfite</z:chebi> genomic sequencing and the methylation special polymerase chain reaction, and evaluated its correlation with clinicopathological characteristics </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> statistical tests were 2-sides </plain></SENT>
<SENT sid="6" pm="."><plain>Downregulation of CADM1/TSLC1 expression was observed in 7 of 8 (88%) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines and in 39 of 54 (72%) primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Hypermethylation of CADM1/TSLC1 promoter region occurred in 6 of 8 (75%) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines and 32 of 54 (59%) primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp>, and was correlated with advanced colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Epigenetic inactivation of CADM1/TSLC1 gene is a frequent alteration in development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and can be a potential biomarker for molecular staging of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>